To determine genome-wide rearrangements of H3K9me2, we conducted ChIP with anti-H3K9me2 and several control antibodies with normal human granulocytes, normal bone marrow CD34+ hematopoietic progenitors, and K562 human myeloid leukemia cell line (see experimental flowchart in Fig A in S1 File). The gene discussed is CD34; the disease is myeloid leukemia.